drugset
Drugs / fasoracetam
last change Nov 2018 re-read 3 minutes ago

fasoracetam

also known as NFC-1 · AEVI-001 · LAM-105 · LAM-105 ANHYDROUS · NFC-1 ANHYDROUS · NS-105

Small molecule

Developed for
attention deficit-hyperactivity disorder · 22q11.2 deletion syndrome
Investigated by
Aevi Genomic Medicine, LLC, a Cerecor company · Children's Hospital of Philadelphia · Pearson/Clinical Assessment · Thomas Jefferson University

Trials 6

today NCT03609619 · Ph 2 NCT03265119 · Ph 2 NCT03006367 · Ph 1 NCT02895906 · Ph 1 NCT02777931 · Ph 2/3 NCT02286817 · Ph 1
2015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 13 trials
Phase 1 NCT03006367 Jan → Feb 2017 attention deficit-hyperactivity disorder Aevi Genomic Medicine, LLC, a Cerecor company Completed No outcome recorded
Phase 1 NCT02895906 Nov 2016 → Apr 2017 22q11.2 deletion syndrome Aevi Genomic Medicine, LLC, a Cerecor company Completed No outcome recorded
Phase 1 NCT02286817 Jan → May 2015 attention deficit-hyperactivity disorder Aevi Genomic Medicine, LLC, a Cerecor company Completed No outcome recorded
Phase 22 trials
Phase 2 NCT03609619 Aug → Nov 2018 attention deficit-hyperactivity disorder Aevi Genomic Medicine, LLC, a Cerecor company Completed No outcome recorded
Phase 2 NCT03265119 Aug 2017 → Sep 2018 attention deficit-hyperactivity disorder Aevi Genomic Medicine, LLC, a Cerecor company Completed No outcome recorded
Phase 2/31 trial
Phase 2/3 NCT02777931 Jun 2016 → Feb 2017 attention deficit-hyperactivity disorder Aevi Genomic Medicine, LLC, a Cerecor company Completed No outcome recorded

Evidence & citations 10 cited values

Every value below carries the sentence it was read from. 7 sources stand behind the page.

FieldValueCited text
Known as fasoracetam “This 5-week, open-label, single-blind, placebo-controlled study reports the safety, pharmacokinetics and responsiveness of the metabotropic glutamate receptor (mGluR) activator...” PMID 29339723 ↗ Jan 2018
Known as AEVI-001 ClinicalTrials.gov intervention name — accepted as the source's own label NCT03609619 ↗
1

NCT03265119 ↗
Known as LAM-105 ChEMBL registry synonym — accepted as the source's own label CHEMBL2106179 ↗
Known as LAM-105 ANHYDROUS ChEMBL registry synonym — accepted as the source's own label CHEMBL2106179 ↗
Known as NFC-1 “This 5-week, open-label, single-blind, placebo-controlled study reports the safety, pharmacokinetics and responsiveness of the metabotropic glutamate receptor (mGluR) activator...” PMID 29339723 ↗ Jan 2018
3

NCT03006367 ↗

NCT02895906 ↗

NCT02777931 ↗
Known as NFC-1 ANHYDROUS ChEMBL registry synonym — accepted as the source's own label CHEMBL2106179 ↗
Known as NS-105 ChEMBL registry synonym — accepted as the source's own label CHEMBL2106179 ↗
Action Activate “mGluR activator fasoracetam (NFC-1)” PMID 29339723 ↗ Jan 2018
Modality Small molecule — CHEMBL2106179 ↗
Route Oral “Doses of NFC-1 will be administered as 100, 200, or 400 mg twice daily as capsules for oral administration.” NCT02777931 ↗